Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
News & insights
Publications: 29 JULY 2020
Setting the stage Since long, discussions in Belgium have been ongoing as to who needs to prove that a patient was sufficiently informed about his/her treatment and its potential complications. With…Read more
News: 20 JULY 2020
An A&O team comprising UK, German, U.S. and Dutch lawyers is advising GlaxoSmithKline (GSK) on its strategic collaboration with German biotech company CureVac for the research, development and…Read more
News: 10 JULY 2020
Allen & Overy has advised the joint sponsors on the global offering and listing of shares of Immunotech Biopharm Ltd (Immunotech Biopharm) on the Hong Kong Stock Exchange under Chapter 18A of the…Read more
News: 22 MAY 2020
Allen & Overy has advised Eurofins Scientific (Eurofins) on a successful fundraising through the issuance of new shares and a bond issuance.Read more